Cargando…

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients

Clostridioides difficile infection (CDI) is most commonly diagnosed using nucleic acid amplification tests (NAAT); the low positive predictive value of these assays results in patients colonized with C. difficile unnecessarily receiving CDI treatment antibiotics. The risks and benefits of antibiotic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fishbein, Skye R. S., Hink, Tiffany, Reske, Kimberly A., Cass, Candice, Struttmann, Emily, Iqbal, Zainab Hassan, Seiler, Sondra, Kwon, Jennie H., Burnham, Carey-Ann D., Dantas, Gautam, Dubberke, Erik R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845614/ https://www.ncbi.nlm.nih.gov/pubmed/33441409 http://dx.doi.org/10.1128/mSphere.00936-20

Ejemplares similares

691. Association between Clostridioides difficile Colonization, Rectal Swab NAAT Positivity, and Environmental Contamination
por: Lee, Mary Morgan, et al.
Publicado: (2023)

Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis
por: Fishbein, Skye RS, et al.
Publicado: (2022)

1796 Recovery of Clostridium difficile, Vancomycin Resistant Enterococcus and Methicillin Resistant Staphylococcus aureus from the Food of Hospitalized Patients
por: Kwon, Jennie H., et al.
Publicado: (2014)

1773. Impact of Antibiotics Used to Treat Community Acquired Pneumonia on the Gut Microbiome and Resistome in Healthy Volunteers
por: Anthony, Winston, et al.
Publicado: (2018)

2847. Comparative Genomics and Clonal Tracking of Multi-drug-Resistant Uropathogens Implicates the Fecal Microbiome as a Potential Reservoir for Recurrent Urinary Tract Infections
por: Thanert, Robert, et al.
Publicado: (2019)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

Comparative Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of Urinary Tract Infections
por: Thänert, Robert, et al.
Publicado: (2019)

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study
por: Langdon, Amy, et al.
Publicado: (2021)

Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults
por: Anthony, Winston E., et al.
Publicado: (2022)

2322: The effects of fecal microbiota transplantation on the gut microbiota in subjects with Clostridium difficile infection
por: Elizabeth Langdon, Amy, et al.
Publicado: (2018)

Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
por: Bulow, Christopher, et al.
Publicado: (2018)

2570. A Randomized Controlled Trial of Lactobacillus rhamnosus GG on Multidrug-Resistant Organism (MDRO) Colonization
por: Rauseo, Adriana M, et al.
Publicado: (2019)

Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection Following Subsequent Antibiotic Exposure: A Case Report
por: Keen, Eric C, et al.
Publicado: (2020)

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
por: Kwak, Suryang, et al.
Publicado: (2020)

Risk factors for hospital-onset Clostridioides difficile infections before and during the severe acute respiratory syndrome coronavirus 2 pandemic
por: Kwon, Jennie H., et al.
Publicado: (2023)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period
por: Dubberke, Erik R., et al.
Publicado: (2017)

Draft Genome Sequence of a Mycobacterium Strain Isolated from a Clinical Wound Sample
por: Ransom, Eric M., et al.
Publicado: (2022)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease
por: Dubberke, Erik R., et al.
Publicado: (2006)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

2411. One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease
por: Papic, Neven, et al.
Publicado: (2019)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Bogdanová, Kateřina, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
por: Sahrmann, John M, et al.
Publicado: (2023)

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

Epidemiology of Plasmid Lineages Mediating the Spread of Extended-Spectrum Beta-Lactamases among Clinical Escherichia coli
por: Mahmud, Bejan, et al.
Publicado: (2022)

Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis
por: Muhammad, Aziz, et al.
Publicado: (2020)

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients
por: Bao, Hongkai, et al.
Publicado: (2020)

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?
por: Kim, Jieun, et al.
Publicado: (2022)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile
por: Wultańska, Dorota, et al.
Publicado: (2020)

Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection
por: Zhang, Kevin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gnpmk9drvr4c2fd0m2kb2btn13